287 related articles for article (PubMed ID: 33611977)
1. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.
Garcia-Romeu A; Barrett FS; Carbonaro TM; Johnson MW; Griffiths RR
J Psychopharmacol; 2021 Apr; 35(4):353-361. PubMed ID: 33611977
[TBL] [Abstract][Full Text] [Related]
2. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
[TBL] [Abstract][Full Text] [Related]
3. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
[TBL] [Abstract][Full Text] [Related]
4. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
[TBL] [Abstract][Full Text] [Related]
5. Dose-response relationships of psilocybin-induced subjective experiences in humans.
Hirschfeld T; Schmidt TT
J Psychopharmacol; 2021 Apr; 35(4):384-397. PubMed ID: 33663259
[TBL] [Abstract][Full Text] [Related]
6. Replication and extension of a model predicting response to psilocybin.
Russ SL; Carhart-Harris RL; Maruyama G; Elliott MS
Psychopharmacology (Berl); 2019 Nov; 236(11):3221-3230. PubMed ID: 31203401
[TBL] [Abstract][Full Text] [Related]
7. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
Barrett FS; Johnson MW; Griffiths RR
J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
[TBL] [Abstract][Full Text] [Related]
8. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.
Carbonaro TM; Johnson MW; Griffiths RR
Psychopharmacology (Berl); 2020 Aug; 237(8):2293-2304. PubMed ID: 32500212
[TBL] [Abstract][Full Text] [Related]
9. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
[TBL] [Abstract][Full Text] [Related]
10. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
[TBL] [Abstract][Full Text] [Related]
11. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.
Erritzoe D; Barba T; Spriggs MJ; Rosas FE; Nutt DJ; Carhart-Harris R
J Psychopharmacol; 2024 May; 38(5):458-470. PubMed ID: 38520045
[TBL] [Abstract][Full Text] [Related]
12. Body mass index (BMI) does not predict responses to psilocybin.
Spriggs MJ; Giribaldi B; Lyons T; Rosas FE; Kärtner LS; Buchborn T; Douglass HM; Roseman L; Timmermann C; Erritzoe D; Nutt DJ; Carhart-Harris RL
J Psychopharmacol; 2023 Jan; 37(1):107-116. PubMed ID: 36373934
[TBL] [Abstract][Full Text] [Related]
13. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
Griffiths R; Richards W; Johnson M; McCann U; Jesse R
J Psychopharmacol; 2008 Aug; 22(6):621-32. PubMed ID: 18593735
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
[TBL] [Abstract][Full Text] [Related]
15. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
[TBL] [Abstract][Full Text] [Related]
16. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu A; Griffiths RR; Johnson MW
Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
[TBL] [Abstract][Full Text] [Related]
17. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
Lyvers M; Meester M
J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.
Brown RT; Nicholas CR; Cozzi NV; Gassman MC; Cooper KM; Muller D; Thomas CD; Hetzel SJ; Henriquez KM; Ribaudo AS; Hutson PR
Clin Pharmacokinet; 2017 Dec; 56(12):1543-1554. PubMed ID: 28353056
[TBL] [Abstract][Full Text] [Related]
19. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
Griffiths RR; Johnson MW; Richards WA; Richards BD; Jesse R; MacLean KA; Barrett FS; Cosimano MP; Klinedinst MA
J Psychopharmacol; 2018 Jan; 32(1):49-69. PubMed ID: 29020861
[TBL] [Abstract][Full Text] [Related]
20. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
